Jupiter Neurosciences Inc. (JUNS)
NASDAQ: JUNSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
JUNS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.63M
- Forward P/E
- 20.58
- EPS (TTM)
- -$22.53
- Dividend yield
- None
- 52-week range
- 1.20 – 97.73
- Day range
- 1.20 – 1.46
- Volume / Avg
- 20.11K / 69.86K
- Beta
- —
- Shares outstanding
- 1.32M
52-week range
JUNS stock today
Shares of Jupiter Neurosciences (JUNS) finished lower on Nov 20 at $1.24, a drop of 18.75% or $0.285 per share, versus the S&P 500's 3.70% decline. Trading was light, with 20.11K shares changing hands, about 29% of the average daily volume. At this level, JUNS sits near the bottom of its 52-week range of $1.20 to $97.73: 98.7% below the high and 2.9% above the low.
Jupiter Neurosciences has posted a net loss over the last twelve months (EPS of -$22.53), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Jupiter Neurosciences
Company profileJupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Christer Rosen
- Headquarters
- Jupiter, FL
- Employees
- 5
- IPO year
- 2024
- Website
- jupiterneurosciences.com
Financial highlights
Full financialsIn fiscal 2025, Jupiter Neurosciences generated $21,796 in revenue, up 0.0% from fiscal 2024. Jupiter Neurosciences reported a net loss of $8.6 million, compared with a loss of $2.4 million a year earlier. Gross margin was 80.6% and operating margin -40873.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $21.80K | $0 | — |
| Growth | — | — | — |
| Net income | $-8.64M | $-2.44M | $-4.78M |
| EPS (diluted) | $-0.25 | $-0.08 | $-0.18 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $-6.02 vs —
Jupiter Neurosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRFXPRF Technologies Ltd. | 0.4758 | -23.68% | $1.66M | vs JUNS |
| KALAKALA BIO Inc. | 2.71 | -10.28% | $1.74M | vs JUNS |
| SBFMSunshine Biopharma Inc. | 2.23 | -5.11% | $1.84M | vs JUNS |
| APVOAptevo Therapeutics Inc. | 0.4041 | -2.37% | $1.40M | vs JUNS |
| PPBTPurple Biotech Ltd. ADR | 1.53 | -4.09% | $1.86M | vs JUNS |
| PPCBPropanc Biopharma Inc. | 1.78 | +3.19% | $1.87M | vs JUNS |
| XRTXXORTX Therapeutics Inc. | 0.839 | -5.73% | $1.88M | vs JUNS |
| EOCNEocene Ltd. | 1.78 | +1.73% | $1.90M | vs JUNS |
Indexes, lists and sector
Jupiter Neurosciences stock FAQ
What is Jupiter Neurosciences's stock price today?
JUNS last traded at $1.24 as of Nov 20, 4:00 PM EST, down 18.75% on the day. Prices are delayed at least 15 minutes.
Who is Jupiter Neurosciences's CEO?
Mr. Christer Rosen is the chief executive officer of Jupiter Neurosciences Inc., which has about 5 employees.
What is the JUNS 52-week high?
The 52-week high for JUNS is $97.73 and the 52-week low is $1.20. The stock is currently 98.7% below its high.